WTA
BMRN icon

Washington Trust Advisors’s BioMarin Pharmaceuticals BMRN Stock Holding History

Washington Trust Advisors’s Portfolio BMRN Stock Details BMRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-117
Closed -$6.43K – 695
2025
Q2 		$6.43K Sell
117
-135
-54% -$7.95K ﹤0.01% 541
2025
Q1 		$17.8K Hold
252
– – ﹤0.01% 406
2024
Q4 		$16.6K Buy
252
+65
+35% +$4.35K ﹤0.01% 423
2024
Q3 		$13.1K Buy
187
+28
+18% +$2.34K ﹤0.01% 447
2024
Q2 		$13.1K Hold
159
– – ﹤0.01% 435
2024
Q1 		$13.9K Hold
159
– – ﹤0.01% 435
2023
Q4 		$15.3K Buy
159
+41
+35% +$3.63K ﹤0.01% 425
2023
Q3 		$10.4K Buy
118
+21
+22% +$1.87K ﹤0.01% 456
2023
Q2 		$8.41K Hold
97
– – ﹤0.01% 483
2023
Q1 		$9.43K Sell
97
-53
-35% -$5.49K ﹤0.01% 508
2022
Q4 		$15.5K Sell
150
-301
-67% -$28.3K ﹤0.01% 450
2022
Q3 		$38K Hold
451
– – ﹤0.01% 421
2022
Q2 		$37K Buy
451
+82
+22% +$6.53K ﹤0.01% 443
2022
Q1 		$29K Sell
369
-265
-42% -$22.2K ﹤0.01% 530
2021
Q4 		$56K Buy
+634
New +$52.3K ﹤0.01% 451

Other funds holding BMRN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Washington Trust Advisors's BMRN Position: Q3 2025 in Review

Washington Trust Advisors sold out of BioMarin Pharmaceuticals (BMRN) in Q3 2025, closing a stake of 117 shares — an estimated $6.43K sold.

Washington Trust Advisors first reported a position in BMRN in Q4 2021 and held it in 15 quarters. The position peaked at $56K in Q4 2021. 576 funds tracked by Wall St. Rank hold BMRN as of Q3 2025.

  • Washington Trust Advisors reported no remaining BioMarin Pharmaceuticals position as of Q3 2025 after selling out during the quarter.
  • Washington Trust Advisors sold 117 BioMarin Pharmaceuticals shares in Q3 2025, an estimated $6.43K.
  • Washington Trust Advisors first reported a position in BioMarin Pharmaceuticals in Q4 2021 and held it in 15 quarters.
  • Washington Trust Advisors's BioMarin Pharmaceuticals position peaked at $56K in Q4 2021.
  • 576 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q3 2025.

Based on Washington Trust Advisors's 13F filing for Q3 2025, filed 10 Nov 2025.